Mesenchymal stem cell therapies - Stempeutics

Drug Profile

Mesenchymal stem cell therapies - Stempeutics

Alternative Names: ex-vivo cultured adult human mesenchymal stem cells - Stempeutics; ex vivo cultured adult allogenic mesenchymal stem cells - Stempeutics; ex-vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells - Stempeutics; Stempeucel; stempeucel AMI™; stempeucel CLI™; stempeucel COPD™; stempeucel CS™; stempeucel DCM™; stempeucel DM™; stempeucel LC™; stempeucel OA™

Latest Information Update: 26 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stempeutics
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes - Osteoarthritis; Peripheral ischaemia

Highest Development Phases

  • Marketed Peripheral ischaemia
  • Phase II Osteoarthritis
  • No development reported Chronic obstructive pulmonary disease; Dilated cardiomyopathy; Liver cirrhosis; Myocardial infarction; Stroke; Type 2 diabetes mellitus

Most Recent Events

  • 26 Jun 2018 Launched for Peripheral ischaemia in India (IM)
  • 07 Mar 2018 Stempeutics Research plans a phase IV post-marketing surveillance trial for Peripheral ischaemia (For critical limb ischemia due to Buerger's disease) in India (CTRI/2018/02/011839)
  • 05 Apr 2017 Stempeutics withdrew a phase II trial prior to enrolment as DCGI directed to conduct PMS study for Peripheral ischemia (In adults) in India (NCT03056742)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top